Navigation Links
Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
Date:4/5/2010

dy temperature and learned of 4-aminopyridine, or dalfampridine, which blocks the potassium ion channels in nerve fibers.

"The chemical was commonly used in physiology laboratories where scientists were studying normal nerve conduction, but at the time it was used clinically only by physicians in Bulgaria, then a Communist-block country," Davis said. "They didn't know how it worked, but they used it to help patients recover from anesthesia-induced paralysis more quickly."

In 1983, in a small proof-of-concept study, Davis and Stefoski injected the drug in 11 patients whose motor function and eyesight were impaired because of multiple sclerosis.

"It was stunning," Stefoski said. "After a single intravenous dose, the patients could walk better and see better."

Rush was granted market exclusivity by the FDA under the Orphan Drug Act of 1983 and licensed worldwide rights for dalfampridine first to Ireland-based Elan Corporation and subsequently to Acorda Therapeutics, Inc., located in Hawthorne, New York. This month, Acorda began marketing dalfampridine in the U.S. under the brand name Ampyra.

In two Phase III clinical trials conducted by Acorda, the drug yielded a consistent improvement in walking speed. Walking speed increased by about 25 percent in 35 percent of patients in one trial and in 43 percent of patients in the other, as measured by a standard test called the Timed 25-Foot Walk. Study participants who took the drug also experienced greater leg strength than those who took a placebo.

Stefoski said that although the drug has been approved specifically for the treatment of impaired walking, it also relieves other symptoms of multiple sclerosis, since it restores signal conduction in all the affected nerve fibers.

Multiple sclerosis is a chronic, often disabling autoimmune disease. According to the National Multiple Sclerosis Society, more than 2.5 million people worldwide and 400,00
'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
3. Clinical course of subepithelial lesions
4. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
5. NHLBI funds preclinical tests on devices for infants and children with congenital heart defects
6. Medpedia Launches New Clinical Trial Platform
7. Most Antidepressants Miss Key Target of Clinical Depression
8. Banner Health Systems Adopts Quantros Regulatory Reporting Management (RRM) to Manage Clinical Quality and Performance Data and Support Improvements in Quality of Care
9. Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information
10. European Cancer Organization supports a revision of the EU Clinical Trials Directive
11. Roche and Catalyst Resources Team to Explore RIA Healthcare Collaboration Solutions for Enhanced Clinical Diagnosis and Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer more affordable ... the premier online supplier of elegant special occasion dresses ... huge selection of sexy prom dresses today. In addition ... many beautiful styles in its product line. Click to ... , “VogueQueen.com hopes to provide a truly unique shopping ...
(Date:11/27/2014)... Aliso Viejo, California (PRWEB) November 27, 2014 ... have announced a new plugin entitled ProPip, taking FCPX to ... picture in picture effect with a few clicks of a ... is a time saver that our users will appreciate.” , ... with full customization leaving the possibilities truly endless. ProPip is ...
(Date:11/27/2014)... 2014 HealthPostures, a leading ... , has announced that it has entered into ... The partnership will put HealthPostures' products into central ... In addition to having its products sold through ... HealthPostures' products with the business decision makers in ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... pediatric combination for, immunization against diphtheria, tetanus, pertussis, polio and ... ... Pa. and LYON, France, June 23 Sanofi,Pasteur, the vaccines ... and Drug Administration (FDA) has licensed Pentacel(R),Diphtheria and Tetanus Toxoids ...
... decrease in health care and compensation benefits, ... economy, employers are managing to maintain a balance ... Survey released today by,the Society for Human Resource ... health care costs, combined with the state of ...
... NEW YORK, June 21 Many professionals,world-wide are calling ... force fluoridation on almost the whole state. SB 312 ... most Louisianans knowing,it was happening. The professionals are asking ... Citizens should have been part of this discussion,but they ...
... DELHI, India, June 20 The United States,has ... Save the Children to assist people affected by ... Shortages have emerged in recent months because ... in rapidly growing rat infestations in,crop-growing areas. With ...
... San Francisco,Medical Society (SFMS) announces the "David Perlman ... is presented each January at,the SFMS Annual Dinner ... television, radio and newspapers and magazines. The deadline ... award., A prestigious panel of SFMS journalists, ...
... life is greatly improved, too, , , FRIDAY, June 20 ... for many people with kidney disease, it can be ... blood as effectively as well-functioning kidneys do. , But, ... to change all that. , Nocturnal dialysis, not surprisingly, ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Despite Economic Downturn, Employee Benefits Remain Stable in 2008 2Health News:Professionals Ask Governor Jindal to Veto Unfair Fluoridation Bill 2Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 2Health News:Nocturnal Dialysis: A Better Way to Kidney Health 3
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... Calif. and LONDON , Nov. ... and AstraZeneca (NYSE: AZN ) today announced that ... two doses of brodalumab in more than 1,800 patients with ... both Stelara ® (ustekinumab) and placebo at week 12. ... weight-based analysis group were each shown to be superior to ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... MINNEAPOLIS, Sept. 29 ProUroCare Medical Inc. (OTC Bulletin ... imaging products, today announced the signing of an agreement ... LP of Juno Beach, Fla.  The proceeds of the ... portfolio and to support scale-up activities associated with final ...
... PROSPECT, Ill., Sept. 29 Earlier this year, the National ... was introduced to the AWARxE campaign, which was created and ... the power of the campaign, NABP obtained the AWARxE program ... level. The Foundation was inspired to create ...
Cached Medicine Technology:UPDATE - ProUroCare Announces $3 Million Financing Agreement 2UPDATE - ProUroCare Announces $3 Million Financing Agreement 3NABP Purchases AWARxE Consumer Protection Program 2
Sonogage introduces a new generation of A-Scan biometers for visual axis measurements and IOL calculations. The Eye-Scan™ employs the latest electronic and transducer technologies for unsurpass...
... three conventional measurement modes (Phakic, Aphakic, and ... new axial length measuring mode. Normal phakic ... velocity for conversion at 1550m/s. The new ... each tissues sonic velocity for conversion: anterior ...
... the world's first very high frequency digital ... technology, Artemis provides microscopic resolution images and ... anterior segments of the human eye. Artemis ... eye scanner. In use, the patient leans ...
... The new OTI-Scan 1000 is the ... compact combination B/A-scan system operates with a ... performs 3D B-scans with a streamlined internal ... 1000 is newly designed. The UltraFast 12 ...
Medicine Products: